936901-73-4

Usage

Uses

Used in Medicinal Chemistry:
3-(8-bromo-1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone is used as a potential lead compound for the development of new drugs due to its unique structure and potential biological activities.
Used in Drug Discovery:
In the field of drug discovery, 3-(8-bromo-1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone is utilized as a starting point for the synthesis of novel heterocyclic compounds with potential therapeutic applications.
Used in Chemical Research:
3-(8-bromo-1-chloroH-pyrrolo[1,2-a]pyrazin-6-yl)cyclobutanone is employed as a subject of study in chemical research to understand the reactivity and properties of similar heterocyclic compounds, which can contribute to the advancement of synthetic chemistry and the development of new pharmaceutical agents.

Upstream product

• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 939412-84-7 N-[(2-chlorophenyl(methyl))]-3-oxocyclobutanecarboxamide 
• 939412-81-4 3-oxocyclobutanecarboxylic acid 2,5-dioxopyrrolidin-1-yl ester 
• 936901-72-3 3-(8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone 

Downstream Products

• 936901-74-5 cis-3-(1-bromo-8-chloro-imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol 
• 936901-75-6 cis-3-(8-amino-1-bromo-imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol 
• 867160-71-2 linsitinib 
• 1356958-77-4 cis-8-amino-3-(3-hydroxy-3-methyl-cyclobutyl)-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-7-ium chloride 
• 1356958-93-4 cis-8-amino-3-(3-hydroxy-3-methyl-cyclobutyl)-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-7-ium methanesulfonate 

Relevant academic research and scientific papers

CYCLOALKYLIDENE CARBOXYLIC ACIDS AND DERIVATIVES AS BTK INHIBITORS

The present invention relates to novel cycloalkylidene carboxylic acids and derivatives thereof useful as Bruton tyrosine kinase (BTK) inhibitors. The present disclosure also relates to processes for their preparation, pharmaceutical compositions containing one or more such compounds, and to the use of such compounds and pharmaceutical compositions for the treatment of disorders involving mediation of BTK in humans (Formula I).

PROTEIN KINASE INHIBITORS

The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the Tec or Src protein kinase families. The present invention also relates to the processes of preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.

Discovery of novel insulin-like growth factor-1 receptor inhibitors with unique time-dependent binding kinetics

This letter describes a series of small molecule inhibitors of IGF-1R with unique time-dependent binding kinetics and slow off-rates. Structure-activity and structure-kinetic relationships were elucidated and guided further optimizations within the series

Fused bicyclic mTOR inhibitors

Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.

Process to prepare substituted imidazopyrazine compounds

A method of preparing wherein, X=Cl, Br, I, comprises the step of treating with N-chloro-, N-bromo-, or N-iodosuccinimide in a compatible solvent such as dimethylformamide (DMF) at 0-60° C. followed by halogenation.

Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors

The present invention provides a method for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein the agent is an mTOR inhibitor, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein said agent is an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. The present invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA?).